In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
The European Commission (EC) has granted full Marketing Authorization for Reblozyl (luspatercept), for treatment in adult patients of anemia associated with non-transfusion-dependent (NTD) beta thalassemia, US pharma major Bristol Myers Squibb announced on Friday. 4 March 2023
Biotechnology
Curie Bio, which launched last month as a new venture model in biotech, today announced that Chris De Savi, an expert practitioner of drug discovery and drug discovery executive, has joined the firm as a CSO Partner. 3 March 2023
Pharmaceutical
Exelixis has announced the failure of the Phase III CONTACT-03 study of Cabometyx (cabozantinib), in kidney cancer. 3 March 2023
Pharmaceutical
The global cancer vaccines market is expected to garner a market value of $9 billion in 2023 and is expected to accumulate a market value of $24.22 billion by registering a compound annual growth rate (CAGR) of 12% in the forecast period 2023 to 2033. 3 March 2023
Biotechnology
A merger between Flamingo Therapeutics and Dynacure will create a new oncology company, retaining the Flamingo name, advancing lead candidates danvatirsen and FTX-001. 3 March 2023
Generics
Taiwan generics drugmaker Lotus Pharmaceuticals has received approval in Vietnam for its cancer drug vinorelbine soft gel in two varieties - 20mg and 80mg- to compete with the branded version Navelbine, originated by French drugmaker Pierre Fabre. 3 March 2023
Biotechnology
A judge in the USA has dismissed litigation against Bristol Myers Squibb, alleging the New York-based company defrauded former Celgene shareholders out of $6.4 billion. 3 March 2023
Pharmaceutical
Despite strong protest from the UK pharmaceutical sector, including several companies quitting the scheme, the government has confirmed plans to raise the revenue clawback rate paid by firms subject to the Statutory Scheme for branded medicines from 24.4% to 27.5%. 3 March 2023
Biotechnology
Swedish rare disease specialist Hansa Biopharma today announced today that Matthew Shaulis will join the company effective March 16 as chief commercial officer and president of its US affiliate 3 March 2023
Biosimilars
Belgian biotech Galapagos’ suffered a disappoint earlier this month, when its already commercialized JAK inhibitor Jyseleca (filgotinib) fell short in the induction cohorts of a Phase III Crohn's disease (CD) trial. 3 March 2023
Biotechnology
G-protein coupled receptor (GPCR) company Confo Therapeutics has announced a worldwide licensing agreement with US pharma major Eli Lilly for the Belgian firm’s clinical stage CFTX-1554 and back-up compounds. 2 March 2023
Biotechnology
USA-based Ambrx Biopharma and partner NovoCodex Biopharmaceuticals have announced an update on ACE-Breast-02, a Phase III breast cancer trial. 2 March 2023
Biotechnology
Dutch autoimmune diseases specialist argenx said today that Karen Massey will join the company as chief operating officer COO, effective March 13, 2023. 2 March 2023
Pharmaceutical
Markets were not hugely worried by predictions for a tough 2023 for Merck KGaA, with the German company’s share price only marginally down late Thursday. 2 March 2023
Pharmaceutical
Florida, USA-based Avenue Therapeutics, which was founded by Fortress Biotech, today announced that it has entered into an exclusive license agreement with AnnJi Pharmaceutical, a Taiwanese clinical-stage drug company. 2 March 2023
Pharmaceutical
Following in the steps of other big insulin producers, US pharma major Eli Lilly yesterday announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket costs at $35 0or less per month. 2 March 2023
Biotechnology
Results from the Phase III VANGUARD study evaluating garadacimab (CSL312) as a once-monthly, prophylactic treatment for attacks due to hereditary angioedema (HAE) met its primary and secondary endpoints, demonstrating that monthly subcutaneous injections of garadacimab significantly reduced the attack rate compared to placebo. 2 March 2023
Pharmaceutical
A report from the second edition of the AmpleLogic Pharma Summit, held last month at Hilton Cairo Heliopolis in Egypt. 2 March 2023
Biotechnology
The US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the available data support the safety and effectiveness of UK pharma major GSK’s respiratory syncytial virus (RSV) older adult vaccine candidate for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 years and older. 2 March 2023
Biotechnology
Research from industry analyst GlobalData finds that while generics currently dominate the market for lupus treatments, a change is on the way led by new biologics. 2 March 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze